Skip to Main content Skip to Navigation
Journal articles

Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir

Abstract : Influenza infections remain a burden on health care systems despite vaccination programs and marketed antiviral drugs. Immunomodulation through activation of innate sensors could represent innovative approaches to fight the flu. This study evaluated the ability of flagellin, agonist of Toll-like receptor 5 (TLR5), to control the replication of influenza A virus (IAV) in mice. First, we showed that systemic or intranasal administration of flagellin activated transcription of anti-viral genes in lung tissue. Prophylactic and therapeutic flagellin administration resulted in decreased levels of viral RNA and infectious virus in the lungs of H3N2 IAV-infected mice. The effect of the flagellin on viral replication was also observed in Ifnar-/- and Il22-/- IAV-infected mice, suggesting a mechanism independent of type I interferon and interleukin 22 signaling. In addition, a combination therapy associating the neuraminidase inhibitor oseltamivir and flagellin was more effective than standalone treatments in reducing pulmonary viral replication. Thus, this study highlights the therapeutic potential of the flagellin to control the replication of the influenza virus.
Document type :
Journal articles
Complete list of metadata

https://hal-univ-tours.archives-ouvertes.fr/hal-03365055
Contributor : Christophe Paget Connect in order to contact the contributor
Submitted on : Tuesday, October 5, 2021 - 10:18:24 AM
Last modification on : Tuesday, October 19, 2021 - 11:56:32 PM

Links full text

Identifiers

Collections

Citation

Anne-France Georgel, Delphine Cayet, Andrés Pizzorno, Manuel Rosa-Calatrava, Christophe Paget, et al.. Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir. Antiviral Research, Elsevier Masson, 2019, 168, pp.28-35. ⟨10.1016/j.antiviral.2019.05.002⟩. ⟨hal-03365055⟩

Share

Metrics

Record views

9